SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-18-013784
Filing Date
2018-11-06
Accepted
2018-11-06 16:24:01
Documents
57
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20180930x10q.htm 10-Q 866758
2 EXHIBIT 31.1 mrtx093018ex311.htm EX-31.1 12409
3 EXHIBIT 31.2 mrtx093018ex312.htm EX-31.2 12873
4 EXHIBIT 32.1 mrtx093018ex321.htm EX-32.1 8238
  Complete submission text file 0001628280-18-013784.txt   3646143

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20180930.xml EX-101.INS 740549
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20180930.xsd EX-101.SCH 29104
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20180930_cal.xml EX-101.CAL 48811
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20180930_def.xml EX-101.DEF 85359
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20180930_lab.xml EX-101.LAB 326808
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20180930_pre.xml EX-101.PRE 179801
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 181163308
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1